SCHEMBL470985

SCHEMBL470985

COC(=O)c1cc2nc(Cl)c(NNC(=O)CC3CC3)nc2cc1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 4/20 0.39
HSD17B10 Q99714 2/20 0.39
TSHR P16473 2/20 0.39
MAPT P10636 1/20 0.39
P2RX7 Q99572 3/20 0.37
LCK P06239 1/20 0.34
PGK1 P00558 3/20 0.33
KMT2A Q03164 3/20 0.32
MEN1 O00255 2/20 0.32
GRM1 Q13255 1/20 0.31
PTGER4 P35408 1/20 0.31
LMNA P02545 2/20 0.31
USP2 O75604 1/20 0.31
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
ADRA2A P08913 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
ADRA1D P25100 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15374852 0.88 ALDH1A1 (0.38) ALDH1A1KDM4EHSD17B10TSHRMAPT
SCHEMBL12060112 0.88 ALDH1A1 (0.38) ALDH1A1KDM4EHSD17B10TSHRMAPT
SCHEMBL470984 0.82 DYRK1A (0.36) ALDH1A1KDM4EMAPTP2RX7GRM1
SCHEMBL12043375 0.82 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10TSHRMAPT
SCHEMBL10053819 0.82 GAA (0.42) ALDH1A1KDM4EHSD17B10MAPTP2RX7
SCHEMBL7900279 0.81 P2RX7 (0.41) ALDH1A1KDM4EHSD17B10TSHRP2RX7
SCHEMBL12043380 0.80 ALDH1A1 (0.39) ALDH1A1KDM4EHSD17B10TSHRMAPT
SCHEMBL7899497 0.79 ALDH1A1 (0.36) ALDH1A1KDM4EHSD17B10MAPTKMT2A
SCHEMBL15103221 0.78 NPC1 (0.35)
SCHEMBL15374849 0.78 GRM1 (0.33) ALDH1A1KDM4EPGK1GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8901126-B2 Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases ASTELLAS PHARMA INC. (JP) 2014-12-02 US disclosed
US-8674096-B2 Substituted imidazo[1,5-a]quinoxalin-4-ones as phosphodiesterase 9 inhibitors ASTELLAS PHARMA INC. (JP) 2014-03-18 US disclosed
US-20130296329-A1 QUINOXALINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-11-07 US disclosed
US-20130085134-A1 QUINOXALINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-04-04 US disclosed
US-20130085134-A1 QUINOXALINE COMPOUND ASTELLAS PHARMA INC. (JP) 2013-04-04 US disclosed
US-8357688-B2 Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones as PDE9 inhibitors ASTELLAS PHARMA INC. (JP) 2013-01-22 US disclosed
WO-2012033101-A1 QUINOXALINE COMPOUND アステラス製薬株式会社 (JP) 2012-03-15 WO disclosed
US-20110319385-A1 QUINOXALINE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085134-A1 QUINOXALINE COMPOUND PDE9A, PDE2A, PDE3A ALDH1A1 387/4885KDM4E 1337/4885HSD17B10 1309/4885
US-20130296329-A1 QUINOXALINE COMPOUND PDE9A, PDE5A, PDE2A ALDH1A1 764/4885KDM4E 630/4885HSD17B10 2495/4885
US-20110319385-A1 QUINOXALINE COMPOUND PDE9A, PDE5A, PDE3A ALDH1A1 1344/4885KDM4E 641/4885HSD17B10 2831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.